Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo …
…, JD Goldman, J Alatorre-Alexander… - The lancet Respiratory …, 2021 - thelancet.com
Background Baricitinib is an oral selective Janus kinase 1/2 inhibitor with known anti-inflammatory
properties. This study evaluates the efficacy and safety of baricitinib in combination …
properties. This study evaluates the efficacy and safety of baricitinib in combination …
Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide …
…, M Nishio, F Orlandi, J Alatorre-Alexander… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE: IMpower133 (ClinicalTrials.gov identifier: NCT02763579 ), a randomized,
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
double-blind, phase I/III study, demonstrated that adding atezolizumab (anti-programmed death-…
Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non–small-cell lung cancer: the phase III POSEIDON …
…, BC Cho, A Luft, J Alatorre-Alexander… - Journal of Clinical …, 2023 - ascopubs.org
PURPOSE The open-label, phase III POSEIDON study evaluated tremelimumab plus
durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus …
durvalumab and chemotherapy (T + D + CT) and durvalumab plus chemotherapy (D + CT) versus …
[HTML][HTML] Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or …
…, VC Marconi, J Alatorre-Alexander… - The Lancet …, 2022 - thelancet.com
Background The oral, selective Janus kinase 1/2 inhibitor baricitinib has shown efficacy in
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …
studies of hospitalised adults with COVID-19. COV-BARRIER (NCT04421027) was a …
Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double …
H Montgomery, FDR Hobbs, F Padilla… - The Lancet …, 2022 - thelancet.com
Background Early intramuscular administration of SARS-CoV-2-neutralising monoclonal
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …
antibody combination, tixagevimab–cilgavimab, to non-hospitalised adults with mild to …
[HTML][HTML] Usefulness of serum carcinoembryonic antigen (CEA) in evaluating response to chemotherapy in patients with advanced non small-cell lung cancer: a …
…, EO Macedo-Pérez, J Alatorre-Alexander - BMC cancer, 2013 - Springer
Background High serum carcinoembryonic antigen (CEA) levels are an independent
prognostic factor for recurrence and survival in patients with non-small cell lung cancer (NSCLC). …
prognostic factor for recurrence and survival in patients with non-small cell lung cancer (NSCLC). …
[HTML][HTML] Blood first assay screening trial (BFAST) in treatment-naive advanced or metastatic NSCLC: initial results of the phase 2 ALK-positive cohort
…, T Mok, S Peters, JY Han, J Alatorre-Alexander… - Journal of Thoracic …, 2021 - Elsevier
Introduction The Blood First Assay Screening Trial is an ongoing open-label, multicohort
study, prospectively evaluating the relationship between blood-based next-generation …
study, prospectively evaluating the relationship between blood-based next-generation …
[HTML][HTML] Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced …
…, D Rodríguez-Abreu, J Alatorre-Alexander… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
… Andrea Ardizzoni, corresponding author 1 Sergio Azevedo, 2 Belen Rubio-Viqueira, 3
Delvys Rodríguez-Abreu, 4 Jorge Alatorre-Alexander, 5 Hans JM Smit, 6 Jinming Yu, 7 …
Delvys Rodríguez-Abreu, 4 Jorge Alatorre-Alexander, 5 Hans JM Smit, 6 Jinming Yu, 7 …
National consensus of diagnosis and treatment of non-small cell lung cancer
…, A Acosta-Espinoza, J Alatorre-Alexander… - … clinica; organo del …, 2013 - europepmc.org
A comment on this article appears in"[Science and confidence: the need to be clear]." Rev
Invest Clin. 2014 Jan-Feb; 66 (1): 93-4. A comment on this article appears in"[Science and …
Invest Clin. 2014 Jan-Feb; 66 (1): 93-4. A comment on this article appears in"[Science and …
[HTML][HTML] Baricitinib plus standard of care for hospitalized adults with COVID-19
…, MLB Piruzeli, JD Goldman, J Alatorre-Alexander… - MedRxiv, 2021 - medrxiv.org
… Jorge Alatorre-Alexander served as a speaker and scientific advisor for Astra Zeneca,
Boehringer Ingelheim, BMS, Eli Lilly and Company, Foundation Medicine, Novartis, MSD, Roche …
Boehringer Ingelheim, BMS, Eli Lilly and Company, Foundation Medicine, Novartis, MSD, Roche …